Genetic panel for assessing breast and ovarian cancer risk genes.
Some families may have an increased risk of developing certain types of cancer through the inheritance of variants (mutations) in certain genes. Testing for these genetic variants can determine whether a patient might be at increased risk of developing cancer and suggest an appropriate prevention or surveillance strategy. This test is Medicare eligible for those patients satisfying testing criteria.
There are now Medicare rebates available for testing in women with breast and ovarian cancer who are at high (>10%) risk for detecting a genetic cause.
Breast/Ovarian Cancer Gene Panel – BRAoVO™
Used to:
1. Determine presence of pathogenic variations in patients with a personal and/or family history suggestive of high risk (>10%) of having Hereditary Breast and Ovarian Cancer Syndrome.
2. Determine presence of pathogenic variations in patients with a biological relative with a confirmed pathogenic variation in one or more of the genes specified below
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
Massively Parallel Sequencing
4 weeks
$449 when not Medicare eligible
Cancer Genetics request form preferred. Standard pathology request form accepted.
Blood x 2
6mL EDTA
2 x Bloods taken at 10 minute intervals. Pre test genetic counselling required. Patient to sign consent form prior to testing.
